1. Home
  2. PHGE vs XRTX Comparison

PHGE vs XRTX Comparison

Compare PHGE & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$0.20

Market Cap

4.7M

Sector

Health Care

ML Signal

HOLD

Logo XORTX Therapeutics Inc.

XRTX

XORTX Therapeutics Inc.

HOLD

Current Price

$2.01

Market Cap

4.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHGE
XRTX
Founded
2015
2011
Country
United States
Canada
Employees
20
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7M
4.3M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
PHGE
XRTX
Price
$0.20
$2.01
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.2M
10.6K
Earning Date
05-15-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$0.35
52 Week High
$8.50
$3.60

Technical Indicators

Market Signals
Indicator
PHGE
XRTX
Relative Strength Index (RSI) 26.06 42.51
Support Level N/A $0.37
Resistance Level $0.65 $2.28
Average True Range (ATR) 0.02 0.09
MACD 0.02 -0.00
Stochastic Oscillator 4.58 20.83

Price Performance

Historical Comparison
PHGE
XRTX

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is a company focused on acquiring and further developing technologies that identify, track, and counter physical threats across defense, security, critical infrastructure, and first-response sectors. The Company's portfolio is built around the growing need for earlier and more accurate threat detection, particularly as UAVs and other autonomous systems play a larger role in defense and homeland security.

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.

Share on Social Networks: